Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomized Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases.